NervGen Pharma Corp.

As of June 30, 2026, NervGen Pharma Corp. carries a market capitalization of 219.21M, placing it among publicly traded companies globally. Its enterprise value stands at 158.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NervGen Pharma Corp.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, NervGen Pharma Corp. has 106.41M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, NervGen Pharma Corp. maintains a current ratio of 1.23, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -115.68, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 10.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, NervGen Pharma Corp. generated - - in revenue and converted that into -43.66M in net income, yielding earnings per share of -0.54. EBITDA reached -22.72M, while operating income came in at -22.76M.

These figures are as of June 30, 2026. Total book value stands at 12.17M, with working capital of 11.91M providing operational flexibility.

NervGen Pharma Corp. produced -18.07M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.85: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -31.71, meaning NervGen Pharma Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, NervGen Pharma Corp. has an Altman Z-Score of -1.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.